RxSight Lowers Full-Year Sales Guidance to $110-$120M, Citing Q2 Competitive Pressures
RXST is trading near its 52-week low of $4.48 (13% above the low).
Summary
RxSight announced preliminary Q2 2026 results, projecting total revenue of $32-$34 million, including $5-$7 million from its new Alcon collaboration. The company has significantly lowered its full-year sales guidance for 2026 to $110-$120 million, down from a previous range of $120-$135 million, and an even earlier projection of $140-$160 million. This reduction is attributed to "meaningful commercial headwinds" and increased competitive trialing experienced during Q2. Despite the revenue challenges, RxSight raised its gross margin guidance to 73%-75% from the prior 70%-72%. This update follows a Q1 where the company reported an 18.5% revenue decrease and a wider net loss, highlighting ongoing challenges in its core business even as the Alcon partnership contributes new revenue streams. Investors are awaiting further details during the Q2 earnings call scheduled for tomorrow, July 7th.
At the time of this announcement, RXST was trading at $5.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231.8M. The 52-week trading range was $4.48 to $13.65. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.